Your browser doesn't support javascript.
Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan.
Hara, Hisao; Uemura, Yukari; Hayakawa, Kayoko; Togano, Tomiteru; Asai, Yusuke; Matsunaga, Nobuaki; Terada, Mari; Ohtsu, Hiroshi; Kitajima, Koji; Shimizu, Yousuke; Sato, Lubna; Ishikane, Masahiro; Kinoshita-Iwamoto, Noriko; Shibata, Taro; Kondo, Masashi; Izumi, Kazuo; Sugiura, Wataru; Ohmagari, Norio.
  • Hara H; Department of Cardiology, National Centre for Global Health and Medicine, Tokyo, Japan. Electronic address: hhara@hosp.ncgm.go.jp.
  • Uemura Y; Biostatistics Section, Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Hayakawa K; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Togano T; Department of Haematology, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Asai Y; AMR Clinical Reference Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Matsunaga N; AMR Clinical Reference Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Terada M; Biostatistics Section, Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Ohtsu H; Biostatistics Section, Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Kitajima K; Biostatistics Section, Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Shimizu Y; Biostatistics Section, Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Sato L; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Ishikane M; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Kinoshita-Iwamoto N; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Shibata T; Biostatistics Division, Centre for Research Administration and Support, National Cancer Centre, Tokyo, Japan.
  • Kondo M; Centre for Clinical Trial and Research Support, Fujita Health University, Aichi, Japan.
  • Izumi K; Biostatistics Section, Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan.
  • Sugiura W; Biostatistics Division, Centre for Research Administration and Support, National Cancer Centre, Tokyo, Japan.
  • Ohmagari N; Department of Haematology, National Centre for Global Health and Medicine, Tokyo, Japan; Biostatistics Division, Centre for Research Administration and Support, National Cancer Centre, Tokyo, Japan.
Int J Infect Dis ; 112: 111-116, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1654533
ABSTRACT

OBJECTIVES:

To determine whether anticoagulation therapy improves outcomes in patients with coronavirus disease 2019 (COVID-19) in Japan given their lower risk of thrombosis compared with Western cohorts.

METHODS:

The efficacy of anticoagulation therapy in hospitalized patients with COVID-19 was evaluated using a nationwide registry the COVID-19 Registry Japan. The inverse probability of weight treatment method was used to adjust for baseline confounders in the anticoagulation and non-anticoagulation groups.

RESULTS:

Of the 1748 patients included, anticoagulants were used in 367 patients (treatment group). The patients in the anticoagulant group were older, predominantly male, and often presented with obesity, hyperlipidaemia, hypertension, diabetes and elevated D-dimer levels. Twenty-nine-day mortality was 7.6% in the whole cohort (treatment group, 11.2%; no treatment group, 6.6%), 6% in patients who were not treated with steroids (treatment group, 12.3%; no treatment group, 5.2%), and 11.2% in patients treated with steroids (treatment group, 10.5%; no treatment group, 11.8%). Mortality in the whole cohort was similar between the treatment and no treatment groups (P=0.99), and an insignificant decreasing trend in mortality was observed in patients treated with steroids (P=0.075).

CONCLUSIONS:

Anticoagulants may be beneficial in Asians, in whom comorbidities and risk of thrombosis may differ from other ethnic groups.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Male Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Male Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article